← Back to Stock Screener← Stock Screener

ZYBERNO

Stock Report

Updated Sep 1, 2026

Evolent Health, Inc. (EVH)

NYSE

$4.60

Professional Investment Analysis

ZYBERNO SCORE →

Is it a great business? Is it getting better?

24.0/100

POOR BUSINESS

Evolent Health, Inc. (EVH) scores 24/100 — concerning metrics indicating significant structural or financial risks.

📊 How is the Zyberno Score calculated? +

The Zyberno Score answers one question: "Is this a quality business worth owning?" It's a 0-100 investment grade that evaluates business fundamentals across four critical dimensions, based on principles from Warren Buffett, Benjamin Graham, Peter Lynch, and Charlie Munger.

The 4 Core Categories (25 points each):

1. PROFITABILITY (25 pts)

Metrics: ROE, ROIC, Net Margin, Operating Margin
Thresholds: ROE >20% excellent • ROIC >20% excellent • Net Margin >20% excellent • Operating Margin >25% excellent

2. FINANCIAL STRENGTH (25 pts)

Metrics: Debt-to-Equity, Current Ratio, Interest Coverage, Altman Z-Score
Thresholds: D/E <0.3 excellent • Current Ratio >2.5 excellent • Interest Coverage >10x excellent • Altman Z >3.0 safe

3. CASH FLOW QUALITY (25 pts)

Metrics: Free Cash Flow, OCF vs Net Income, FCF Margin
Thresholds: Positive & growing FCF excellent • OCF/NI >1.2x excellent (cash earnings exceed accounting)

4. GROWTH & CONSISTENCY (25 pts)

Metrics: Revenue Growth, Net Income Growth, FCF Growth, Piotroski F-Score
Thresholds: Growth via log-linear regression • Piotroski 8-9 excellent, 6-7 good

Score Interpretation:

75-100

GREAT BUSINESS

65-74

GOOD BUSINESS

50-64

AVERAGE BUSINESS

30-49

WEAK BUSINESS

0-29

POOR BUSINESS

→ View full EVH quality analysis & detailed breakdown

VALUATION SIGNAL

N/A (Requires more data)

Requires fair value calculation and current price data

💰 How is Margin of Safety calculated? +

Margin of Safety measures how much discount or premium you're paying relative to a stock's intrinsic value. It's Benjamin Graham's core principle: the larger the margin, the lower your downside risk.

Formula: (Intrinsic Value − Current Price) ÷ Intrinsic Value × 100%

How We Calculate Intrinsic Value (DCF Method):

Step 1: Calculate current Owner Earnings (OCF − Maintenance CapEx)

Step 2: Calculate company-specific growth rate using log-linear regression on 16 quarters of Owner Earnings

Step 3: Project 10 years forward using the calculated growth rate

Step 4: Discount each year's cash flow to present value using 10% discount rate

Step 5: Calculate terminal value using 3% perpetual growth rate

Step 6: Sum all discounted cash flows = Intrinsic Value

What The Percentages Mean:

+50% or more

EXCELLENT — Very undervalued

+25% to +50%

GOOD — Attractive discount

0% to +25%

FAIR — Reasonable value

0% to -25%

CAUTION — Slight premium

-25% or worse

POOR — Overvalued

"Price is what you pay, value is what you get." — Warren Buffett

→ View full EVH valuation analysis · → View full EVH Brina Gap analysis

📈 How is Brina Gap calculated? +

Brina Gap measures the difference between the growth a business can fundamentally sustain and the growth the market is already pricing in.

Formula: Fundamental Growth Rate − Market-Implied Growth Rate

The Two Components:

Fundamental Growth Rate = ROIC × Reinvestment Rate

What the business can sustainably grow at based on how much it reinvests and what return it earns on that capital. Grounded in historical financials.

Market-Implied Growth Rate = Reverse DCF

The growth rate the current Enterprise Value implicitly assumes. Calculated by back-solving a 10-year DCF model (10% WACC, 3% terminal growth) until the present value of projected cash flows equals EV.

What The Gap Means:

Gap > +5% Market Underestimates — potential upside

+2% to +5% Slight Underestimate

-2% to +2% Fairly Priced — market consensus matches fundamentals

-5% to -2% Slight Overestimate

Gap < -5% Market Overestimates — price embeds optimism fundamentals don't support

A positive gap (market underestimates) combined with a positive Margin of Safety is the strongest combined signal — the business is both cheap historically and forward economics are stronger than the price suggests.

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-99.2%)

Debt-to-Equity (Solvency Risk):EXCELLENT (0.02x)

Operating Margin (Operational Efficiency):CRITICAL (-20.4%)

Return on Capital (Capital Efficiency):CRITICAL (-26.0%)

📊 Valuation Trilogy

Three interconnected metrics for complete valuation analysis

Click any metric for full methodology and detailed analysis

Zyberno's Verdict

Evolent Health, Inc. (EVH) stock report — Zyberno Score 24/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY

A. Market Valuation

Market Price & Capitalization (2)

Current Price:4.60

Market Cap:$517.69M

Valuation Multiples (3)

P/B Ratio:1.35x

P/S Ratio:0.25x

Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$1.37B

Price Action & Momentum (3)

12-1 Momentum:

-52.3% (8th pctile)

📈 Click to view full EVH Momentum analysis →

Momentum Percentile:8 / 100

% of 52-Week High:45.6%

B. Profitability Assessment

Return Metrics (5)

ROE:

-99.2%

📊 Click to view full EVH ROE analysis →

ROA:-24.6%

Roic:

-26.0%

📊 Click to view full EVH ROIC analysis →

Reinvestment Rate:18.2%

Fundamental Growth Rate (g):-4.7%

Margin Analysis (3)

Operating Margin Ttm:-20.4%

Net Margin Ttm:-24.1%

Ebitda Margin:-12.6%

TTM Performance (3)

Gross Margin Ttm:17.2%

Operating Margin Ttm:-20.4%

Net Margin Ttm:-24.1%

Yield Metrics (2)

Earnings Yield:-$99.35

Dividend Yield:0.0%

C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

Earnings Surprise (SUE):

+0.52

📊 Click to view full EVH Earnings Surprise analysis →

EPS Surprise vs Expected:64.6%

Latest Earnings Filed:2026-08-06

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):10.4%

Cash Flow Growth (Linear) (1)

Operating Cash Flow Growth Rate (Linear):12.6%

D. Financial Stability

Liquidity Ratios (3)

Current Ratio:1.24x

Quick Ratio:1.24x

Cash Ratio:0.23x

Leverage Analysis (3)

Debt To Equity Ttm:0.02x

Debt-to-Equity Ratio:0.02x

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-5.93x

Times Interest Earned:-5.93

Capital Structure (4)

Working Capital:117,677,000.00

Cash And Cash Equivalents:115,703,000.00

Long Term Debt:$966.47M

Net Debt:$852.31M

DIVISION II: FINANCIAL STATEMENTS ANALYSIS

A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $2.10B

Linear Growth: 10.4%

📊 Click to view full EVH Revenue analysis & methodology →

Cost Of Revenue Ttm:$1.74B

Profitability Breakdown (2)

Gross profit TTM: $361.64M

Linear Growth: -9.8%

📊 Click to view full EVH Gross Profit analysis & methodology →

-$427.51M

Bottom Line Performance (3)

-$504.99M

Income Before Tax:-$502.14M

Ebitda Ttm:-264,805,000.00

Operating Expenses (5)

Operating Expenses:2,524,523,000.00

R And D Expense:0.00

Sga Expense:291,897,000.00

Income Tax Expense:$2.85M

Interest Expense:69,212,000.00

Expense Ratios (3)

R And D To Revenue Percentage:0.0%

Sga To Revenue Percentage:44.7%

Ebitda Margin:-12.6%

B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$1.97B

Current Assets:$610.51M

Ppe Net:298,276,000.00

Goodwill:694,434,000.00

Intangible Assets:$554.43M

Liability Structure (4)

Total Liabilities:1,588,671,000.00

Current Liabilities:492,833,000.00

Long Term Debt:$966.47M

Short Term Debt:$1.54M

Equity & Capital (3)

Equity:$383.22M

Retained Earnings:-$1.37B

Common Stock:750,000,000.00

Working Capital Items (3)

Accounts Receivable:449,118,000.00

Inventory:0.00

Accounts Payable:38,823,000.00

Special Items (2)

Contract Liabilities:1,208,000.00

Stock Based Compensation:15,201,000.00

C. Cash Flow Analysis

Operating Activities (2)

Operating cash flow TTM: $33.29M

Linear Growth: 12.6%

$0.00

Investment Activities (1)

Investing Cash Flow:-$6.41M

Financing Activities (3)

Financing Cash Flow:-$3.97M

Dividends Paid Ttm:0.00

Stock Repurchase:39,996,000.00

Capital Transactions (3)

Common Stock Issuance:0.00

Long Term Debt Issuance:$0.00

Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:162,700,000.00

DIVISION III: OPERATIONAL METRICS

A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-4.57

-$4.57

Earnings Per Share Ttm:-$4.49

Revenue & Cash Per Share (2)

Sales Per Share Ttm:18.63

Operating Cash Flow Per Share:$0.35

Book Value & Capital (2)

Book Value Per Share:$3.41

Cash Per Share:1.03

Dividend Policy (1)

Dividend Payout Ratio:-999.00x

B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:1.02x

Working Capital Turnover Ttm:17.82x

Receivables Management (2)

Receivables Turnover Ttm:4.67x

Days Sales Outstanding Ttm:78.17

Inventory Management (2)

Inventory Turnover Ttm:-999.00x

Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:8.17

Cash Conversion Cycle:-928.99

C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:20.00

Quality Score:30.00

Market Metrics (2)

Beta:0.00x

Volatility Category:unknown

DIVISION IV: INVESTMENT ANALYSIS

A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:18.2%

Fundamental Growth Rate (g):-4.7%

B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):10.4%

Cash Flow Growth Rates (1)

Operating Cash Flow Growth Rate (Linear):12.6%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):-9.8%

Book Value Growth Rate (Linear):-10.9%

C. Company Profile & Context

Corporate Information (6)

Symbol:EVH

Company Name:Evolent Health, Inc.

Sector:Unknown

Industry:Services-Management Services

Exchange:NYSE

Country:United States

Market Classification (3)

Market Cap Category:N/A

Price Category:low

Volume Category:N/A

Share Structure (3)

Shares Outstanding:112.54M

Shares Outstanding Basic:112.54M

Shares Outstanding Diluted:112.54M

Data Processing Info (3)

Processing Version:v3.0

Last Updated:2026-09-01 22:36:23 UTC

Data Timestamp:2026-09-01T22:36:23.021800